Global Bioengineered Protein Drugs Market to Reach $329.9 Billion by 2030
The global market for Bioengineered Protein Drugs estimated at US$232.5 Billion in the year 2022, is projected to reach a revised size of US$329.9 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2022-2030. Therapeutic Proteins, one of the segments analyzed in the report, is projected to record a 4.1% CAGR and reach US$129.2 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Monoclonal Antibodies segment is readjusted to a revised 4.5% CAGR for the next 8-year period.
The U.S. Market is Estimated at $63.3 Billion, While China is Forecast to Grow at 7.4% CAGR
The Bioengineered Protein Drugs market in the U.S. is estimated at US$63.3 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$69.4 Billion by the year 2030 trailing a CAGR of 7.4% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 1.4% and 5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 2.3% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$44.3 Billion by the year 2030.Select Competitors (Total 56 Featured) -
- Abbott India Ltd.
- Amgen, Inc.
- Bayer AG
- Biocon Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Panacea Biotec Ltd.
- ProBioGen AG
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Bioengineered Protein Drugs - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Bioengineered Protein Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 3: World 18-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Monoclonal Antibodies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 6: World 18-Year Perspective for Monoclonal Antibodies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Therapeutic Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 9: World 18-Year Perspective for Therapeutic Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 12: World 18-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 15: World 18-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for CROs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 18: World 18-Year Perspective for CROs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Academics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 21: World 18-Year Perspective for Academics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 22: World Bioengineered Protein Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
UNITED STATES
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 25: USA 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 28: USA 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 31: Canada 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 34: Canada 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
JAPAN
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 35: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Japan Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 37: Japan 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 40: Japan 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
CHINA
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 41: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: China Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 43: China 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 46: China 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
EUROPE
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 47: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Bioengineered Protein Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 49: Europe 18-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 52: Europe 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 55: Europe 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
FRANCE
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 56: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: France Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 58: France 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 61: France 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
GERMANY
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Germany Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 64: Germany 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 67: Germany 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Italy Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 70: Italy 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 73: Italy 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
UNITED KINGDOM
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: UK Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 76: UK 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 79: UK 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
SPAIN
- Table 80: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Spain Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 82: Spain 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 83: Spain Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Spain Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 85: Spain 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
RUSSIA
- Table 86: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Russia Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 88: Russia 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 89: Russia Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Russia Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 91: Russia 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 94: Rest of Europe 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 97: Rest of Europe 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
ASIA-PACIFIC
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 100: Asia-Pacific 18-Year Perspective for Bioengineered Protein Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Bioengineered Protein Drugs by Type - Therapeutic Proteins, Monoclonal Antibodies and Vaccines Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 103: Asia-Pacific 18-Year Perspective for Bioengineered Protein Drugs by Type - Percentage Breakdown of Value Sales for Therapeutic Proteins, Monoclonal Antibodies and Vaccines for the Years 2012, 2023 & 2030
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Bioengineered Protein Drugs by End-Use - Pharma & Biotech Companies, CROs and Academics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 106: Asia-Pacific 18-Year Perspective for Bioengineered Protein Drugs by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, CROs and Academics for the Years 2012, 2023 & 2030
AUSTRALIA
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Bioengineered Protein Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott India Ltd.
- Amgen, Inc.
- Bayer AG
- Biocon Ltd.
- Dr. Reddy's Laboratories Ltd.
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Novartis International AG
- Panacea Biotec Ltd.
- ProBioGen AG
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 193 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 232.5 Billion |
| Forecasted Market Value ( USD | $ 329.9 Billion |
| Compound Annual Growth Rate | 4.5% |
| Regions Covered | Global |
